Setting clinical MIC breakpoints from a PK/PD point of view: It is the dose that matters

Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics

Volumn 9780387756134, Issue , 2014, Pages 45-61

  Mouton, Johan W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breakpoints ; Clinical trial; Pharmacodynamic target

Indexed keywords

EID: 84920736880     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-75613-4_3     Document Type: Chapter

References (45)

1. Ambrose PG, Grasela DM, Grasela T.H., Passarell J., Mayer HB, Pierce P.F. (2001) Pharmacodynamics of fluoroquinolones against streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 45:2793-2797
2. Ambrose PG, Bhavnani SM, Owens RC Jr (2003) Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 17:529-543
3. Ambrose PG, Bhavnani SM, Rubino CM et al (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86
4. Ambrose PG, Anon JB, Bhavnani SM et al (2008) Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis 61:13-20
5. Bhat S.V., Peleg AY, Lodise TP Jr et al (2007) Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 51:4390-4395
6. Bhavnani SM, Passarell JA, Owen J.S., Loutit JS, Porter SB, Ambrose P.G. (2006) Pharmacokineticpharmacodynamic relationships describing the efficacy of oritavancin in patients with staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50:994-1000
7. Bonate PL (2001) A brief introduction to monte carlo simulation. Clin Pharmacokinet 40:15-22
8. Bruggemann RJ, Donnelly JP, Aarnoutse RE et al (2008) Therapeutic drug monitoring of voriconazole. Ther Drug Monit 30:403-411
9. Bruggemann RJ, van der Linden JW, Verweij PE, Burger DM, Warris A (2011) Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 30:533-534
10. Craig WA (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89-96
11. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-10, quiz 11-12
12. Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17:479-501
13. den Hollander J.G., Fuursted K, Verbrugh H.A., Mouton J.W. (1998) Duration and clinical relevance of postantibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 42:749-754
14. Drusano GL, D'Argenio DZ, Preston SL et al (2000) Use of drug effect interaction modeling with monte carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 44:1655-1659
15. Drusano GL, Preston SL, Hardalo C et al (2001) Use of preclinical data for selection of a phase ii/ iii dose for evernimicin and identification of a preclinical mic breakpoint. Antimicrob Agents Chemother 45:13-22
16. EUCAST (2006) Eucast technical note on daptomycin. Clin Microbiol Infect 12:599-601
17. EUCAST (2005) The eucast process of setting breakpoints. CLSI Subcommittee on Antimicrobial Susceptibility Testing, Tampa, FL
18. Highet VS, Forrest A, Ballow C.H., Schentag J.J. (1999) Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 43(Suppl A):55-63
19. ISO (2006) Iso 20776-1. Clinical laboratory testing and in vitro diagnostic test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility testing devices - part 1. International Standards Organisation
20. Kahlmeter G, Brown DF, Goldstein FW et al (2003) European harmonization of mic breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52:145-148
21. Kahlmeter G, Brown DF, Goldstein FW et al (2006) European committee on antimicrobial susceptibility testing (eucast) technical notes on antimicrobial susceptibility testing. Clin Microbiol Infect 12:501-503
22. Kashuba AD, Nafziger AN, Drusano G.L., Bertino JS Jr (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 43:623-629
23. Lee BL, Sachdeva M, Chambers H.F. (1991) Effect of protein binding of daptomycin on mic and antibacterial activity. Antimicrob Agents Chemother 35:2505-2508
24. MacGowan AP, Noel A, Tomaselli S., Elliott H, Bowker K. (2011a) Pharmacodynamics of razupenem (pz601) studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:1436-1442
25. MacGowan AP, Noel AR, Tomaselli S, Elliott H.C., Bowker K.E. (2011b) Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:867-873
26. Meagher AK, Passarell JA, Cirincione BB et al (2007) Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 51:1939-1945
27. Merrikin DJ, Briant J, Rolinson G.N. (1983) Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 11:233-238
28. Mouton JW, Punt N. (2001) Use of the t>mic to choose between different dosing regimens of betalactam antibiotics. J Antimicrob Chemother 47:500-501
29. Mouton JW, Schmitt-Hoffmann A, Shapiro S., Nashed N, Punt N.C. (2002) Monte carlo predictions of dosage regimens for bal 5788, a new broad-spectrum cephalosporin active against mrsa. In: Interscience conference antimicrobial agents chemotherapy. American Society Microbiology, San Diego, CA
30. Mouton JW, Schmitt-Hoffmann A, Shapiro S., Nashed N, Punt N.C. (2004) Use of monte carlo simulations to select therapeutic doses and provisional breakpoints of bal 9141. Antimicrob Agents Chemother 48:1713-1718
31. Mouton JW, Punt N, Vinks A.A. (2005) A retrospective analysis using monte carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 27:762-772
32. Mouton JW, Punt N, Vinks A.A. (2007) Concentration-effect relationship of ceftazidime explains why the time above the mic is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 51:3449-3451
33. Mouton JW, Ambrose PG, Canton R et al (2011) Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 14:107-117
34. Mouton JW, Brown DF, Apfalter P et al (2012) The role of pharmacokinetics/pharmacodynamics in setting clinical mic breakpoints: the eucast approach. Clin Microbiol Infect 18:E37-E45
35. Muller AE, Schmitt-Hoffmann A, Punt N., Mouton J.W. (2013) Monte carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study. Antimicrob Agents Chemother 57:2047-2053
36. Muller AE, Punt N, Mouton J.W. (2013) Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68(4):900-906
37. Podolsky SH (2010) Antibiotics and the social history of the controlled clinical trial, 1950-1970. J Hist Med Allied Sci 65(3):327-367
38. Roberts JA, Kirkpatrick CM, Roberts M.S., Robertson TA, Dalley AJ, Lipman J. (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142-150
39. Rodriguez-Tudela J.L., Almirante B, Rodriguez-Pardo D et al (2007) Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidaemia. Antimicrob Agents Chemother 51(10):3599-3604
40. Shepard RM, Falkner F.C. (1990) Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 25(Suppl A):49-60
41. Tam VH, Nikolaou M. (2011) A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol 7:e1001043
42. Tam VH, Kabbara S, Vo G., Schilling AN, Coyle E.A. (2006) Comparative pharmacodynamics of gentamicin against staphylococcus aureus and pseudomonas aeruginosa. Antimicrob Agents Chemother 50:2626-2631
43. Tam VH, Ledesma KR, Chang K.T., Wang TY, Quinn J.P. (2009) Killing of escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis 64:166-171
44. Zhanel GG, Dueck M, Hoban DJ et al (2001) Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61:443-498
45. Zhanel GG, DeCorby M, Noreddin A et al (2003) Pharmacodynamic activity of azithromycin against macrolide-susceptible and - resistant streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52:83-88